These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38038416)

  • 1. Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
    Zhang M; Qi W; Qiu X; Yu C; Qiu W; Wang S; Qiu Z
    Radiol Oncol; 2023 Dec; 57(4):419-429. PubMed ID: 38038416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
    Holster JJ; El Hassnaoui M; Franssen S; IJzermans JNM; de Jonge J; Mostert B; Polak WG; de Wilde RF; Homs MYV; Groot Koerkamp B
    Ann Surg Oncol; 2022 Sep; 29(9):5528-5538. PubMed ID: 35294656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review.
    Belkouz A; Nooijen LE; Riady H; Franken LC; van Oijen MGH; Punt CJA; Erdmann JI; Klümpen HJ
    Cancer Treat Rev; 2020 Dec; 91():102110. PubMed ID: 33075684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
    Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
    Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
    Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
    Front Immunol; 2022; 13():940009. PubMed ID: 35874708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
    JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis.
    Niu S; Zhang Y; Li Z; Wang T
    Liver Int; 2024 Sep; 44(9):2208-2219. PubMed ID: 38829010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma.
    Madzikatire TB; Heng S; Gu H; Shan Y; Lin E; Banda J; Debora A; Madziva BA; Bowa MJ; Mudhuri MG; Bwalya C
    Front Immunol; 2024; 15():1390887. PubMed ID: 38846939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
    Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
    BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional therapy containing surgery in metastatic breast cancer: Systematic review and meta-analysis.
    Rahmani J; Elhelali A; Yousefi M; Chavarri-Guerra Y; Ghanavati M; Shadnoush M; Akbari ME; Ardehali SH; Akbari A; Barragan-Carrillo R; Hadizadeh M
    Surgeon; 2024 Feb; 22(1):43-51. PubMed ID: 37858431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis.
    Edeline J; Lamarca A; McNamara MG; Jacobs T; Hubner RA; Palmer D; Groot Koerkamp B; Johnson P; Guiu B; Valle JW
    Cancer Treat Rev; 2021 Sep; 99():102258. PubMed ID: 34252720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Xu H; Zhang H; Li B; Chen K; Wei Y
    BMC Cancer; 2024 Aug; 24(1):1008. PubMed ID: 39143584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.
    Zeng ZC; Tang ZY; Fan J; Zhou J; Qin LX; Ye SL; Sun HC; Wang BL; Li D; Wang JH; Zeng MS; Guo W; Tan YS
    Cancer J; 2006; 12(2):113-22. PubMed ID: 16630402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of carbohydrate antigen 19-9 response with radiologic response and survival in intrahepatic cholangiocarcinoma: A prospective cohort study.
    Cai QY; Yang P; Yang XL; Zhang XH; Guo LP; Lu XY; Huo L; Ma HB; Wang XD; Zhou HB; Wu L; Jia NY
    Cancer; 2023 Oct; 129(19):2999-3009. PubMed ID: 37449788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy.
    Pandey A; Mohseni A; Shaghaghi M; Pandey P; Rezvani Habibabadi R; Hazhirkarzar B; Ly A; Panid Madani S; Borhani A; Kamel IR
    Eur J Radiol; 2024 Jan; 170():111196. PubMed ID: 38029705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Local and locoregional treatment of intrahepatic cholangiocarcinoma].
    Wacker F; Dewald C
    Radiologe; 2022 Mar; 62(3):247-252. PubMed ID: 34981129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?
    Wang Y; Strazzabosco M; Madoff DC
    Curr Oncol Rep; 2022 Dec; 24(12):1741-1750. PubMed ID: 36255606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma.
    Yu Q; Ungchusri E; Pillai A; Liao CY; Baker T; Fung J; DiSabato D; Zhang M; Liao C; Van Ha T; Ahmed O
    Eur Radiol; 2024 Apr; 34(4):2374-2383. PubMed ID: 37812295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.